- Update from the 5th Edition of the WHO Classification of Nasal, Paranasal, and Skull Base Tumors: Imaging Overview with Histopathologic and Genetic Correlation
This manuscript reviews the 2022 World Health Organization update on the head and neck tumor classification, emphasizing the importance of molecular data and genetic alterations in sinonasal neoplasms. It includes new entities and changes to the taxonomy and characterization of tumors.
- Utility of Gadolinium-Based Contrast in Initial Evaluation of Seizures in Children Presenting Emergently
The authors aimed to assess the utility of gadolinium-based contrast agents in MR imaging performed for the evaluation of acute pediatric seizure presentation. In their study population, epileptogenic findings were found in 28% of patients, but gadolinium contrast was found to be of limited additive benefit in these patients.
- Performance of Neck Imaging Reporting and Data System (NI-RADS) for Diagnosis of Recurrence of Head and Neck Squamous Cell Carcinoma: A Systematic Review and Meta-analysis
Posttreatment follow-up imaging of head and neck cancer is challenging because of the anatomic complexity of the head and neck region and the operations and posttreatment effects of radiation and chemotherapy that mimic recurrent disease. The Neck Imaging Reporting and Data System (NI-RADS) provides standardized terminology, report structure, and evaluation categories to convey the degree of suspicion of recurrence in the interpretation of imaging studies. This meta-analysis found NI-RADS 3 (high suspicion) has a high diagnostic performance for detecting clinically significant recurrence.
- Validity of the Bern Score as a Surrogate Marker of Clinical Severity in Patients with Spontaneous Intracranial Hypotension
The Bern score quantitatively characterizes brain MR imaging changes in spontaneous intracranial hypotension. This imaging biomarker was shown to have a low correlation with clinical headache severity and, therefore, imaging findings in isolation may have limited utility as primary outcome measures when assessing treatment response.